Efficacy and safety of apremilast in patients with psoriasis and psoriatic arthritis
Apremilast is a novel, orally administered, targeted synthetic agent that inhibits PDE4 and secretion of various proinflam- matory cytokines. Apremilast is approved for the treatment of psoriasis and psoriatic arthritis (PsA). Efficacy ans safety of apremilast were shown in the randomized, placebo-controlled clinical trials in several thousands of patients with psoriasis (ESTEEM 1, 2 ) and PsA (PALACE 1-3, ACTIVE). Unlike bio- logic agents, apremilast does not induce formation of neutral- izing antibodies and does not increase the risk of infections.